— Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) reported a loss of $0.08 per share in the fourth quarter of 2019, in line with Wall Street expectation.
— Q4 revenue was flat at $1.2 million, vs. $920,000 expected.
— As at December 31, 2019, Titan had cash and cash equivalents of approximately $5.2 million.
— Launch of Sixmo may be delayed due to the impact of Covid-19.
— TTNP shares gained 4.4% during after-market trading hours.
Most Popular
COVID-19 drove retailers up the digital path years ahead than anticipated
Earlier we looked into how, during the COVID-19 pandemic, retailers saw changing trends in terms of their assortments and how the acceleration of online shopping led many of them to
Snowflake (SNOW) creates a record as the most successful software IPO ever; stock more than doubles
Data is at the heart of business innovation. Recognizing this trend, companies are seeking ways to transform their businesses by capturing, analyzing, and mobilizing data. The public cloud is becoming
Adobe (ADBE) sees new tailwinds as virtual shift gathers steam
The second half has been highly rewarding for design software maker Adobe Inc. (NASDAQ: ADBE) amid stable demand for digital content solutions. The company has remained unaffected by the virus-related